Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00076024

AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer

Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study Of AG-013736 In Combination With Docetaxel Versus Docetaxel Alone In Patients With Metastatic Breast Cancer Preceded By A Phase 1 Evaluation Of The Combination

Sponsor: Pfizer

Conditions Breast Neoplasms

Interventions AG-013736 (axitinib) Docetaxel Placebo

Updated 8 times since 2017 Last updated: Jun 21, 2012 Started: Feb 29, 2004 Primary completion: Jan 31, 2007 Completion: Nov 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Breast Neoplasms, this trial is completed. The trial is conducted by Pfizer and has accumulated 8 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Dec 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Feb 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Bangalore, India , Berkeley, United States , Berlin, Germany , Boston, United States , Chicago, United States , Cleveland, United States , Corvallis, United States , Edmonton, Canada , Essen, Germany and 36 more locations